CLINICAL TRIALS PROFILE FOR BRICANYL

All Clinical Trials for Bricanyl

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	Cystic Fibrosis Trust	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	GlaxoSmithKline	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00220259 ↗	Cystic Fibrosis Withdrawal of Inhaled Steroids Evaluation Study (CF WISE Study)	Completed	Royal Brompton & Harefield NHS Foundation Trust	N/A	2001-05-01	The overall aim of this study is to find out whether taking regular inhaled steroids (eg Pulmicort, Flixotide, Becotide, Becloforte) is good for the lungs of children and adults with cystic fibrosis (CF). Some patients are put on inhaled steroids because they are wheezy despite taking regular bronchodilators (inhaled medicines that help open up the airways eg Ventolin, Bricanyl). Occasionally young children are put on them when they wheeze with colds, and have simply remained on them ever since. However many CF patients have been put onto inhaled steroids because their doctors thought it might reduce the inflammation in the lungs and help improve lung function. This inflammation (which is swelling of the lining of the airways) is known to be important in CF and results from recurrent chest infections. Although it is believed, in theory, that inhaled steroids should be useful for most CF patients, we are not sure how well they work in CF and it has not yet been possible to prove this with standard studies. This would normally involve starting inhaled steroids in patients who have not been taking them. We have therefore taken a different approach, namely to withdraw them from some patients who have been on them for a long time, to see if there is any effect of stopping them. It is important that we answer this question, as we do not want CF patients taking medicines that may be unnecessary. CF patients already have to take many oral and inhaled medicines and if we can cut down this burden, it would be helpful for everyone. Of course, we may find that patients do need these medicines but at least we will then be certain that it is for a good reason. The main hypothesis is that withdrawing inhaled steroids is not associated with an earlier onset of acute chest exacerbations.
NCT00259766 ↗	SHARE - Symbicort and Health Economics in a Real Life Evaluation	Completed	AstraZeneca	Phase 3	2004-04-01	The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.
NCT00326053 ↗	Prevention of Asthma Relapse After Discharge From Emergency	Completed	AstraZeneca	Phase 3	2006-05-01	The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
NCT00989833 ↗	Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients	Completed	AstraZeneca	Phase 2	2009-09-01	1. The primary objective of this study is: - To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol on an as-needed basis compared to the use of terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma 2. The secondary objectives of this study are: - To evaluate the magnitude of the protective effect of the combination of budesonide and formoterol as-needed compared to regular once daily use of budesonide plus terbutaline as-needed on exercise induced bronchoconstriction in adults and adolescents with mild intermittent asthma - To evaluate safety of budesonide/formoterol as-needed, terbutaline as-needed and regular use of budesonide + terbutaline as-needed as terms of adverse event
NCT01141465 ↗	Real-world Effectiveness of Combination Therapy in Asthma	Completed	Mundipharma Research Limited		2001-01-01	This study will evaluate and compare the effectiveness of asthma management in patients with evidence of persistent asthma following a switch in asthma therapy to combination inhaled glucocorticosteroid (ICS) / long-acting bronchodilator (LABA) therapy as either: fixed-combination fluticasone propionate / salmeterol (FP/SAL; Seretide®) via pressurised metered-dose inhaler (pMDI) or dry-powder inhaler (DPI) plus as-needed (prn) reliever therapy (salbutamol as DPI, BAI or pMDI), or fixed-combination budesonide / formoterol (BUD/FOR; Symbicort®) via DPI plus prn reliever therapy (salbutamol as DPI, BAI or pMDI or bricanyl as DPI). The final analysis plan will define exact comparators and age groups to be studied after reviewing baseline data.

Clinical Trial Conditions for Bricanyl

Condition Name

Condition Name for Bricanyl
Intervention	Trials
Asthma	4
Acute Asthma	1
Acute Exacerbation of Chronic Obstructive Airways Disease	1
Cystic Fibrosis	1

Condition MeSH

Condition MeSH for Bricanyl
Intervention	Trials
Asthma	6
Status Asthmaticus	1
Pulmonary Disease, Chronic Obstructive	1
Fibrosis	1

Clinical Trial Locations for Bricanyl

Trials by Country

Trials by Country for Bricanyl
Location	Trials
Canada	10
Sweden	3
Tunisia	3
United Kingdom	2
Norway	1

Trials by US State

Trials by US State for Bricanyl
Location	Trials
New York	1

Clinical Trial Progress for Bricanyl

Clinical Trial Phase

Clinical Trial Phase for Bricanyl
Clinical Trial Phase	Trials
Phase 3	4
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Bricanyl
Clinical Trial Phase	Trials
Completed	7
Terminated	1
Unknown status	1

Clinical Trial Sponsors for Bricanyl

Sponsor Name

Sponsor Name for Bricanyl
Sponsor	Trials
AstraZeneca	4
University of Monastir	2
Yaakov Beilin	1

Sponsor Type

Sponsor Type for Bricanyl
Sponsor	Trials
Other	6
Industry	6

Clinical Trials, Market Analysis, and Projections for Bricanyl

Introduction to Bricanyl

Bricanyl, also known as terbutaline, is a short-acting β2 agonist (SABA) commonly used to treat bronchospasm associated with asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Here, we will delve into the current clinical trials, market analysis, and future projections for Bricanyl.

Clinical Trials Involving Bricanyl

Current Use in Clinical Trials

Bricanyl is often used as a control or comparator in clinical trials evaluating new respiratory treatments. For example, in a study protocol listed on ClinicalTrials.gov, patients enter a 2-4 week run-in period where they are treated with Bricanyl 'as needed' before being randomized to different treatment arms. This approach helps establish a baseline for comparing the efficacy and safety of new treatments against a well-established standard like Bricanyl[5].

Role in Asthma and COPD Studies

In many clinical trials, Bricanyl is used to manage symptoms during the run-in period or as a rescue medication. Its inclusion ensures that patients' symptoms are adequately controlled before they are randomized to the experimental treatment. This method helps in assessing the true efficacy of the new treatment by minimizing the impact of rescue medications on the outcome measures[5].

Market Analysis for Bricanyl

Market Size and Growth

The global inhalable drugs market, which includes Bricanyl, is estimated to be USD 35.8 billion in 2024 and is projected to reach USD 88.4 billion by 2037, growing at a CAGR of 7.2% during the forecast period. The respiratory diseases segment, which accounts for the majority of the market share, is driven by the increasing prevalence of chronic respiratory conditions such as asthma, COPD, and occupational lung diseases[2].

Segmental Growth

The dry powder formulation segment, which includes Bricanyl Turbuhaler, is anticipated to hold a significant revenue share due to its quick effectiveness and patient comfort. Dry powder formulations like Bricanyl Turbuhaler are preferred for their ease of administration and better stability compared to liquid formulations[2].

Regional Market

The North American market, particularly the U.S., is a significant contributor to the sales of inhalable drugs, including Bricanyl. The region's advanced healthcare infrastructure and high investments in research and development activities drive the growth of this market. According to the Centers for Disease Control and Prevention, the prevalence of chronic respiratory disorders such as COPD and asthma continues to fuel the demand for inhalable medications like Bricanyl[2].

Projections for Bricanyl

Increasing Demand for Inhalable Medications

The rising prevalence of respiratory diseases globally is expected to drive the demand for inhalable medications. For instance, in 2019, the prevalence of chronic respiratory diseases was around 454.6 million cases globally, and this number is expected to increase, thereby boosting the demand for drugs like Bricanyl[2].

Competitive Landscape

Bricanyl operates in a competitive market with other inhalable drugs, including combination inhalers that offer enhanced therapeutic benefits. However, its established safety profile and efficacy make it a staple in the treatment of acute bronchospasm. The trend towards combination therapies may influence the market share of Bricanyl, but its role as a quick-relief medication is likely to remain significant[2].

Regulatory and Clinical Trends

The regulatory environment and clinical trial landscape are crucial for the continued success of Bricanyl. As new treatments emerge, Bricanyl may be used as a comparator to establish the efficacy and safety of these new drugs. The absence of significant adverse events, such as interstitial lung disease, associated with Bricanyl further solidifies its position in the market[1][5].

Key Takeaways

• Clinical Trials: Bricanyl is frequently used in clinical trials as a control or rescue medication to manage symptoms and establish a baseline for new treatments.
• Market Analysis: The global inhalable drugs market, including Bricanyl, is projected to grow significantly due to the increasing prevalence of chronic respiratory diseases.
• Segmental Growth: The dry powder formulation segment, which includes Bricanyl Turbuhaler, is expected to hold a significant revenue share due to its ease of use and quick effectiveness.
• Regional Market: The North American market, particularly the U.S., is a key driver of sales for Bricanyl due to its advanced healthcare infrastructure and high prevalence of respiratory disorders.
• Projections: The demand for Bricanyl is expected to remain strong due to its established safety profile and efficacy in treating acute bronchospasm.

FAQs

What is Bricanyl used for?

Bricanyl, or terbutaline, is a short-acting β2 agonist used to treat bronchospasm associated with asthma, COPD, and other respiratory conditions.

How is Bricanyl used in clinical trials?

Bricanyl is often used as a control or comparator in clinical trials to manage symptoms during the run-in period or as a rescue medication to establish a baseline for new treatments.

What is the market size and growth projection for inhalable drugs like Bricanyl?

The global inhalable drugs market is estimated to be USD 35.8 billion in 2024 and is projected to reach USD 88.4 billion by 2037, growing at a CAGR of 7.2%.

Which segment of the inhalable drugs market does Bricanyl belong to?

Bricanyl belongs to the dry powder formulation segment, which is anticipated to hold a significant revenue share due to its quick effectiveness and patient comfort.

What drives the demand for Bricanyl in the North American market?

The demand for Bricanyl in the North American market is driven by the region's advanced healthcare infrastructure, high investments in research and development, and the high prevalence of chronic respiratory disorders.

How does Bricanyl compare to other inhalable medications in terms of safety?

Bricanyl has an excellent safety profile, with no significant adverse events such as interstitial lung disease associated with its use, making it a preferred option for managing acute bronchospasm.

References

1. BriaCell Therapeutics Corp. - BriaCell Presents Clinical Efficacy Data at ASCO 2024 - BioSpace.
2. Research Nester - Inhalable Drugs Market Size & Share, Growth Report 2037.
3. Pharmaceutical Technology - Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of ...
4. Fortune Business Insights - Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032].
5. ClinicalTrials.gov - Study Protocol - ClinicalTrials.gov.

Last updated: 2024-12-31